News | oneAMYLOIDOSISvoice

News

Amyloidosis: Novel Treatments Could Improve Poor Outcomes

Jul 26, 2026

Real-World Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A Pharmacovigilance Study

Jul 26, 2026

A novel method to classify exercise response in patients with cardiac amyloidosis – The RoMa classification

Jul 25, 2026

Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review

Jul 25, 2026

Amyloidosis and Thoracic Aortic Disease: A Scoping Review

Jul 24, 2026

HELIOS-B Trial Finds No Sex-Based Differences in Vutrisiran Efficacy for ATTR-CM

Vutrisiran demonstrated consistent efficacy in both women and men with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), with no statistically significant…

Jul 24, 2026

Immunoglobulin D-associated AL amyloidosis: clinical features and outcomes

Jul 23, 2026

Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality

Jul 23, 2026

Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy

Jul 23, 2026

Experimental treatment reduces toxic heart protein in ATTR-CM trial

Jul 23, 2026

HFSA Cardio Town Hall: Expert Perspectives on Contemporary ATTR-CM Clinical Research

Join this 30-minute Cardio Town Hall, moderated and led by Dr. Mazen Hanna and Dr. Mathew Maurer for an expert discussion on contemporary ATTR-CM clinical research…

Subscribe to

Newsletter